According to radiocarbon calibrated dates, the Early Bronze I (EB 1) lasted almost six centuries, between c. 3,700 and c.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2024 financial ...

The recent announcement by the Tamil Nadu Chief Minister M. K. Stalin that the Iron Age began in Tamil Nadu is a case in point. It is not an accident that the findings of Tamil Nadu archaeologists ...

Deutsche Bank analyst David Hoang initiated coverage of Sarepta (SRPT) with a Hold rating and $136 price target Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2024 financial results after the Nasdaq Global Market ...

Arrowhead (ARWR) announced that the global licensing and collaboration agreement with Sarepta Therapeutics (SRPT) announced on November 26, 2024, has now closed. Closing of the transaction was ...

Sarepta Therapeutics, Inc. has a fifty-two week low of $102.15 and a fifty-two week high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

BEIRUT, Feb 12 (Reuters) - Israel has requested to keep its troops in five posts in southern Lebanon until February 28, a Lebanese official and foreign diplomat told Reuters on Wednesday.

The IDF Spokesperson’s Unit said, “The targets struck were a violation of the understandings between Israel and Lebanon.” “The IDF continues to operate to remove any threat to the State of ...

European regulators are to review Sarepta Therapeutics’ Duchenne muscular dystrophy drug, eteplirsen – a drug that has sparked controversy in the US, where it was approved by the FDA against ...

Along with imposing no upper age limit – a major boost for patients hoping to get access to the drug, as well as to Sarepta – the new decision also converts Elevidys’ accelerated approval ...